hepat
b
viru
hbv
infect
constitut
seriou
public
health
problem
affect
approxim
million
carrier
worldwid
chronic
hbv
infect
significantli
elev
risk
develop
liver
cirrhosi
hepatocellular
carcinoma
current
convent
nucleo
ide
analog
avail
antihbv
agent
howev
ifnbas
therapi
caus
signific
side
effect
yield
longterm
clinic
benefit
less
treat
patient
nucleo
ide
analog
suppress
essenti
step
viru
replic
therebi
provid
biochem
histolog
improv
earli
drug
give
rise
drugresist
virus
advers
affect
longterm
clinic
outcom
thu
order
approach
cur
treatment
new
antihbv
agent
target
differ
molecul
involv
hbv
infect
propag
need
nucleo
ide
analog
suppress
hbv
replic
mainli
inhibit
revers
transcript
process
viral
lifecycl
figur
ifn
function
immunomodul
also
report
directli
interfer
hbv
replic
multipl
step
lifecycl
given
hbv
encod
one
viral
protein
carri
enzymat
activ
polymeras
genom
strategi
inhibit
viral
enzym
limit
although
capsid
envelop
protein
assembl
regulatori
xprotein
possibl
futur
target
critic
develop
new
class
antihbv
agent
identifi
cellular
factor
serv
possibl
drug
target
gener
viral
entri
step
attract
target
develop
antivir
agent
earli
hbv
lifecycl
includ
entri
step
gain
signific
attent
recent
regard
molecular
mechan
trigger
identif
sodium
taurochol
cotransport
polypeptid
ntcp
cellular
entri
receptor
articl
summar
molecular
evid
relat
hbv
entri
mainli
focus
recent
find
implic
hbv
infect
host
hepatocyt
follow
multipl
step
process
initi
hbv
revers
attach
host
cell
surfac
proteoglycan
low
affin
follow
process
involv
specif
receptor
high
affin
mediat
earli
entri
step
endocytosismedi
intern
viru
fuse
cellular
membran
compart
probabl
endosom
compart
although
mechan
fulli
understood
initi
attach
probabl
importantli
specif
receptor
recognit
contribut
host
specif
tissu
tropism
initi
attach
step
least
partli
mediat
heparan
sulfat
proteoglycan
third
intern
step
report
involv
caveola
clathrin
macropinocytosisdepend
endocytosi
depend
cell
type
experiment
system
howev
cellular
factor
involv
highaffin
bind
earli
entri
process
remain
elucid
recent
hbv
surfac
protein
compos
three
protein
term
larg
lhb
middl
mhb
small
shb
surfac
protein
includ
region
lhb
encompass
region
mhb
encompass
shb
compris
region
molecular
requir
hbv
envelop
protein
hbv
infect
studi
decad
use
primari
hepatocyt
human
tupaia
belangeri
well
heparg
cell
seri
analys
use
neutral
antibodi
introduc
point
mutat
suggest
region
play
signific
role
hbv
infect
direct
approach
region
lhb
shown
essenti
involv
hbv
infect
process
demonstr
introduct
mutat
viral
context
infect
competit
antibodi
peptid
mimick
region
myristoyl
peptid
encompass
amino
acid
region
turn
effici
infect
inhibit
hbv
also
envelop
proteinrel
hepat
viru
hdv
peptid
use
tool
character
earli
infect
step
includ
identif
ntcp
entri
receptor
lead
substanc
myrcludexb
present
clinic
develop
see
one
recent
mileston
field
hbv
molecular
biolog
identif
ntcp
host
entri
receptor
report
yan
zhong
et
al
late
affin
purif
mass
spectrometri
analysi
use
hbv
lipopeptid
bait
identifi
tupaia
belangeri
ntcp
tsntcp
cellular
factor
interact
lipopeptid
ntcp
transport
resid
basolater
membran
hepatocyt
involv
hepat
uptak
mostli
conjug
bile
salt
see
lipopeptid
confirm
specif
bind
human
ntcp
hntcp
well
tsntcp
surprisingli
crabeat
monkey
ntcp
mkntcp
correl
speci
specif
hbv
infect
hbv
abl
effici
infect
human
tupaia
crabeat
monkey
interestingli
result
also
correl
vitro
bind
activ
peptid
respect
primari
hepatocyt
vivo
hepatotrop
role
ntcp
viral
infect
hbv
satellit
viru
hdv
close
relat
primat
hepadnaviru
wooli
monkey
hbv
examin
knockdown
overexpress
analys
sirnamedi
knockdown
ntcp
primari
human
hepatocyt
phh
primari
tupaia
hepatocyt
differenti
heparg
cell
reduc
hbv
hdv
infect
ectop
express
ntcp
confer
hbv
suscept
cell
origin
support
effici
infect
strongli
argu
ntcp
essenti
factor
hbv
infect
express
ntcp
differ
cell
consist
hbv
suscept
significantli
express
hbvsuscept
cell
phh
differenti
heparg
cell
weakli
express
absent
hela
cell
show
littl
infect
introduct
ntcp
undifferenti
heparg
cell
confer
hbv
infect
cell
extent
although
total
express
transduc
cell
compar
hntcpexpress
cell
show
much
higher
infect
effici
compar
human
hepatocyt
cell
line
initi
studi
infect
effici
ntcpoverexpress
cell
cultur
medium
contain
dimethyl
sulfoxid
dmso
subsequ
analysi
show
increas
dmso
concentr
augment
infect
effici
evalu
immunofluoresc
hbv
protein
although
viru
inoculum
differ
studi
specul
includ
dmso
augment
gene
express
ntcp
promot
membran
local
ntcp
chang
posttransl
modif
ntcp
detail
molecular
mechan
dmsomedi
promot
hbv
infect
open
studi
remain
unknown
cell
infect
hbv
report
possibl
ntcp
function
support
hbv
entri
reflect
posttransl
modif
subcellular
local
factor
govern
cell
condit
gener
condit
cell
cycl
cellular
microenviron
architectur
anoth
open
question
high
suscept
hdv
hbv
cell
overexpress
hntcp
futur
analysi
issu
necessari
order
establish
cell
cultur
model
suscept
hbv
infect
crucial
amino
acid
sequenc
ntcp
involv
hbv
infect
analyz
sequenc
comparison
hntcp
mkntcp
replac
amino
acid
hntcp
respect
sequenc
mkntcp
abrog
abil
support
hbv
subsequ
infect
mkntcp
carri
convers
region
hntcp
confer
hbv
suscept
thu
amino
acid
ntcp
crucial
ntcpmediat
hbv
bind
infect
also
shown
hntcp
bear
substitut
aa
mous
counterpart
abl
bind
function
hbv
infect
replac
residu
mous
ntcp
mntcp
human
counterpart
support
infect
data
indic
aa
residu
determin
ntcp
function
hbv
entri
receptor
remain
elucid
mntcp
support
hbv
infect
mntcp
shown
support
specif
bind
cell
surfac
although
bind
capac
mntcp
region
appear
weaker
hntcp
possibl
bind
hbv
ntcp
suffici
requir
addit
molecul
mechan
trigger
follow
earli
infect
process
hdv
virusoidlik
particl
depend
hbv
assembl
propag
hdv
share
hbv
envelop
protein
lhb
mhb
shb
attachmentearli
entri
mechan
seem
similar
hbv
due
complet
differ
replic
strategi
like
depend
differ
cellular
factor
follow
differ
pathway
membran
fusion
intriguingli
hdv
infect
observ
complement
hntcp
either
mousederiv
cell
rat
hepatocyt
cell
nonhepatocyt
hela
cho
vero
cell
stark
contrast
hbv
infect
cell
suggest
hbv
requir
addit
host
factor
infect
restrict
postentri
step
prior
coval
close
circular
dna
cccdna
format
particular
interest
clarifi
molecular
mechan
underli
differ
cellular
requir
infect
hbv
hdv
especi
tri
establish
suscept
mous
model
futur
present
unclear
whether
addit
cellular
factor
besid
ntcp
requir
viral
infect
determin
tissu
speci
tropism
hbv
includ
factor
essenti
involv
viral
lifecycl
attach
intern
endocytosi
membran
fusion
uncoat
nuclear
transloc
cccdna
format
affect
postentri
restrict
overexpress
hntcp
mous
hepatocyt
cell
line
cell
confer
suscept
hbv
infect
contrast
hbv
infect
observ
ntcp
introduct
cell
hntcp
confer
effici
hbv
infect
cell
low
effici
infect
observ
undifferenti
heparg
cell
detect
infect
mous
rat
hepatoma
cell
includ
cell
also
show
differ
clone
isol
similarli
express
high
level
ectop
ntcp
like
differ
cellular
genet
background
divers
effici
hbv
infect
observ
favor
exist
addit
host
factor
determin
suscept
hbv
infect
hepat
c
viru
hcv
infect
multipl
cellular
factor
requir
effici
viral
entri
includ
low
densiti
lipoprotein
receptor
ldlr
scaveng
receptor
class
b
type
srbi
occludin
ocln
viral
entri
receptor
niemannpick
epiderm
growth
factor
receptor
egfr
ephrin
factor
involv
entri
report
complement
hocln
requir
render
high
hcv
suscept
mice
furthermor
case
duck
hepat
b
viru
dhbv
multipl
factor
suggest
essenti
effici
viral
infect
carboxypeptidas
confirm
bind
dhbv
envelop
function
viral
attach
entri
howev
overexpress
protein
alon
cell
support
dhbv
infect
carboxypeptidas
abl
bind
dhbv
heron
hbv
infect
primari
duck
hepatocyt
protein
also
express
nonliv
tissu
thu
addit
factor
like
requir
explain
dhbv
suscept
one
candid
includ
duck
ntcp
exampl
virus
util
multipl
receptor
favor
pursu
identif
addit
cellular
factor
crucial
hbv
entri
ntcp
also
design
solut
carrier
famili
member
transport
gene
famili
famili
consist
seven
member
among
ntcp
apic
sodiumdepend
bile
salt
transport
asbt
also
known
sodiumdepend
transport
bile
acid
ntcp
mainli
distribut
basolater
membran
hepatocyt
play
major
role
hepat
influx
conjug
bile
salt
portal
circul
ntcp
plasma
membran
hepatocyt
bind
two
sodium
ion
togeth
one
molecul
preferenti
conjug
bile
salt
uptak
addit
bile
salt
ntcp
like
transport
bind
andor
transport
molecul
includ
steroid
hormon
thyroid
hormon
drugconjug
bile
salt
varieti
xenobiot
hntcp
aa
protein
appar
mass
kda
includ
put
seven
nine
transmembran
domain
predict
topolog
ntermin
extracellular
ctermin
intracellular
end
structur
ntcp
resolv
crystal
structur
asbt
neisseria
mening
asbtnm
yersinia
frederiksenii
asbtyf
recent
report
asbtnm
show
ten
transmembran
domain
hydrophob
inwardfac
bind
caviti
structur
differ
model
hasbt
current
favor
base
bioinformat
predict
experiment
data
carri
seven
nine
transmembran
helic
ntermin
extracellular
ctermin
cytoplasm
domain
structur
analysi
asbtyf
propos
two
conform
inward
outwardopen
structur
bile
salt
transport
rotat
two
core
helic
transmembran
tm
asbtnm
asbtyf
homolog
respect
hasbt
even
lower
homolog
hntcp
uncertain
whether
structur
featur
asbtnm
asbtyf
use
design
drug
target
hasbt
hntcp
sever
singl
nucleotid
polymorph
snp
alter
transport
activ
ntcp
report
nonsynonym
snp
variant
seen
allel
frequenc
african
american
decreas
plasma
membraneloc
ntcp
reduc
transport
activ
variant
seen
allel
frequenc
chines
american
exhibit
almost
complet
loss
function
bile
acid
uptak
possess
normal
transport
activ
nonbil
acid
substrat
estron
sulfat
anoth
report
show
variant
carri
allel
frequenc
korean
respect
decreas
uptak
taurochol
acid
polymorph
depend
ethnic
howev
report
seriou
diseas
associ
defect
ntcp
gene
report
describ
ntcp
knockout
mice
publish
date
thu
difficult
draw
conclus
whether
physiolog
role
ntcp
complement
factor
share
redund
physiolog
function
whether
ntcp
inhibit
abl
safe
serv
antihbv
drug
target
importantli
recent
report
molecular
determin
transport
function
ntcp
overlap
abil
support
hbv
entri
ntcp
mutat
amino
acid
critic
bile
salt
bind
abrog
bind
peptid
infect
hbv
variant
ntcp
could
neither
bind
region
support
hbv
infect
cell
cultur
gener
viral
entri
process
attract
target
develop
antivir
agent
note
aa
region
lhb
protein
import
hbv
infect
myrcludexb
optim
synthet
lipopeptid
consist
myristoyl
aa
region
abl
strongli
inhibit
hbv
infect
cell
cultur
vivo
mous
model
cell
cultur
model
report
approxim
pm
follow
success
clinic
develop
enfuvirtid
first
peptid
hiv
entri
inhibitor
mimick
region
deriv
viral
envelop
glycoprotein
myrcludexb
clinic
develop
phase
ibiia
mechanist
myrcludexb
bind
hntcp
inactiv
receptor
function
hbv
hdv
figur
remark
transport
activ
ntcp
approxim
nm
show
bind
satur
requir
receptor
inactiv
thu
allow
therapeut
window
infect
inhibit
without
complet
abrog
bile
salt
transport
thu
agent
target
ntcp
expect
potent
candid
act
antihbv
drug
cyclosporin
csa
first
line
compound
reveal
inhibit
hbv
infect
target
ntcp
csa
known
immunosuppress
classifi
calcineurin
inhibitor
clinic
use
suppress
immunolog
failur
xenograft
tissu
transplant
cell
cultur
analys
csa
also
report
suppress
replic
numer
virus
includ
hiv
hcv
influenza
viru
sever
acut
respiratori
syndrom
coronaviru
human
papillomaviru
flavivirus
hbv
case
cyclophilin
cyp
cellular
peptidyl
prolyl
cistran
isomeras
catalyz
conform
chang
protein
primari
cellular
target
csa
critic
effici
viral
replic
cyp
inhibit
csa
respons
antivir
activ
howev
antihbv
entri
activ
csa
mediat
inhibit
cyp
rather
via
direct
target
ntcp
csa
bound
ntcp
plasma
membran
inhibit
transport
activ
figur
also
inhibit
bind
lhb
ntcp
vitro
figur
suggest
csa
interact
ntcp
thu
inhibit
recruit
lhb
incom
hbv
ntcp
plasma
membran
block
hbv
entri
antihbv
activ
csa
pangenotyp
moreov
deriv
analysi
identifi
seri
csa
analog
stronger
antihbv
entri
activ
submicromolar
notabl
nonimmunosuppress
csa
analog
may
potent
antihbv
agent
given
nonimmunosuppress
csa
analog
includ
alisporivir
debio
signific
activ
decreas
hcv
viral
load
clinic
trial
regard
promis
antihcv
drug
candid
deriv
analysi
csa
may
reason
approach
drug
develop
exampl
compound
known
ntcp
inhibitor
includ
progesteron
propranolol
bosentan
shown
block
hbv
infect
figur
ntcp
substrat
taurochol
tauroursodeoxychol
bromosulfophthalein
also
inhibit
hbv
infect
anticholesterem
drug
ezetimib
shown
block
hbv
entri
drug
report
inhibit
ntcp
transport
result
indic
compound
modul
ntcp
function
could
substanti
inhibit
hbv
infect
cell
engin
overexpress
ntcp
also
use
highthroughput
screen
identifi
compound
target
ntcp
inhibit
hbv
infect
one
exampl
identifi
chemic
screen
oxysterol
oxid
deriv
cholesterol
byproduct
cholesterol
biosynthesi
hosttarget
antivir
gener
expect
signific
advantag
includ
much
lower
frequenc
drug
resist
univers
antivir
effect
beyond
viral
genotyp
complementari
mechan
action
might
act
synergist
manner
current
avail
antivir
agent
importantli
offer
addit
therapeut
choic
given
ifn
nucleosid
analog
current
avail
antihbv
agent
identif
ntcp
hbv
entri
receptor
acceler
understand
hbv
molecular
biolog
offer
use
experiment
system
analyz
hbv
hdv
lifecycl
includ
identif
host
restrict
depend
factor
ntcp
also
repres
new
therapeut
target
develop
new
antihbv
agent
analys
use
new
cell
cultur
system
necessari
order
clarifi
molecular
mechan
underli
ntcpmediat
hbv
infect
establish
vivo
small
anim
model
fulli
support
hbv
infect
